Focus: Long-term treatment with lamivudine in HBeAg negative patients with chronic hepatitis B: To switch or not to switch?

Journal of Hepatology

Volumn 56, Issue 6, 2012, Pages 1219-1220

  Shouval, Daniel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ANTIVIRAL RESISTANCE; DRUG COST; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER INJURY; MONOTHERAPY; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84861202324     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.03.002     Document Type: Note

References (7)

1. S.L. Doong, C.H. Tsai, R.F. Schinazi, D.C. Liotta, and Y.C. Cheng Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues Proc Natl Acad Sci USA 88 1991 8495 8499 (Pubitemid 21915383)
2. F. Zoulim, and S. Locarnini Hepatitis B virus resistance to nucleos(t)ide analogues Gastroenterology 137 2009 1593 1608
3. F. Zoulim Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 31 Suppl. 1 2011 1478 3231
4. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
5. EASL Clinical Practice Guidelines Management of chronic hepatitis B. European Association For The Study Of The Liver J Hepatol 50 2009 227 242
6. P. Marcellin, J. Sung, and T. Piratvisuth Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon Liver Int 30 2010 657 668
7. M. Fasano, P. Lampertico, A. Marzano, V. Di Marco, G. Anna Niro, and G. Brancaccio HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years J Hepatol 56 2012 36 40